[vc_row full_width=”stretch_row_content” equal_height=”yes”][vc_column width=”1/2″ css=”.vc_custom_1544610110017{padding-right: 50px !important;padding-left: 50px !important;background-color: #2d73b4 !important;}”][vc_row_inner css=”.vc_custom_1513044211520{margin-bottom: 0px !important;}”][vc_column_inner width=”1/2″][vc_single_image image=”1907″ img_size=”full” css=”.vc_custom_1544613131995{margin-bottom: 0px !important;}” el_class=”imgborder”][/vc_column_inner][vc_column_inner width=”1/2″][ultimate_heading main_heading=”Patron in Chief
PSCO” main_heading_color=”#ffffff” sub_heading_color=”#ffffff” alignment=”right” spacer=”line_only” spacer_position=”middle” line_height=”1″ line_color=”#ffffff” main_heading_font_family=”font_family:Poppins|font_call:Poppins|variant:500″ main_heading_style=”font-weight:500;” main_heading_font_size=”desktop:24px;” sub_heading_font_family=”font_family:Poppins|font_call:Poppins|variant:500″ sub_heading_style=”font-weight:500;” sub_heading_font_size=”desktop:24px;” sub_heading_line_height=”desktop:30px;” main_heading_line_height=”desktop:30px;” spacer_margin=”margin-top:24px;margin-bottom:24px;” el_class=”textshadow” main_heading_margin=”margin-top:50px;” sub_heading_margin=”margin-bottom:50px;”]Prof. S. Hassan Manzoor Zaidi[/ultimate_heading][/vc_column_inner][/vc_row_inner][vc_column_text el_class=”whitecolor”]

It gives me immense pleasure to write down about PSCO which we started about 30 years ago. In 1986, a group of renowned international oncologists gathered at Hyderabad under W.H.O for deliberation on oncology for the benefit of Pakistani Oncologists. This triggered a nucleus for formation of a Society of Oncologist in Pakistan. The Pakistan Society of Clinical Oncology came into existence in 2004. Over the years by the grace of all mighty Allah, number has grown into a blooming Society – “The Pakistan Society of Clinical Oncology”. This was a long journey but we achieved it successfully. People will come and go. I wish all the best for this society. I being patron in chief of this society will continue till my health will allow for it. All the best PSCO.

[/vc_column_text][/vc_column][vc_column width=”1/2″ css=”.vc_custom_1544610124950{padding-right: 50px !important;padding-left: 50px !important;background-color: #327abd !important;}”][vc_row_inner css=”.vc_custom_1513044211520{margin-bottom: 0px !important;}”][vc_column_inner width=”1/2″][ultimate_heading main_heading=”President
PSCO” main_heading_color=”#ffffff” sub_heading_color=”#ffffff” alignment=”left” spacer=”line_only” spacer_position=”middle” line_height=”1″ line_color=”#ffffff” main_heading_font_family=”font_family:Poppins|font_call:Poppins|variant:500″ main_heading_style=”font-weight:500;” main_heading_font_size=”desktop:24px;” sub_heading_font_family=”font_family:Poppins|font_call:Poppins|variant:500″ sub_heading_style=”font-weight:500;” sub_heading_font_size=”desktop:24px;” sub_heading_line_height=”desktop:30px;” main_heading_line_height=”desktop:30px;” spacer_margin=”margin-top:24px;margin-bottom:24px;” el_class=”textshadow” main_heading_margin=”margin-top:50px;” sub_heading_margin=”margin-bottom:50px;”]Dr. Mohammad Faheem[/ultimate_heading][/vc_column_inner][vc_column_inner width=”1/2″][vc_single_image image=”1908″ img_size=”full” alignment=”right” css=”.vc_custom_1544612907052{margin-bottom: 0px !important;}” el_class=”imgborder”][/vc_column_inner][/vc_row_inner][vc_column_text el_class=”whitecolor”]

Pakistan Society of Clinical Oncology is a  registered society of all practicing oncologists of Pakistan. Under this umbrella, all clinical oncologists, medical oncologists, hematologists, pediatric oncologists, surgical oncologists, medical physicists and all allied specialties gather once in a year to share their knowledge. I feel quite honored that I was selected president of this society in 2016. We are struggling hard to keep this society updated and encouraging young oncologists of Pakistan to take the leading role. PSCO hold its annual conference every year. Both national and international speakers presents their data. PSCO elects its council after every two years with online election.  My best wishes are with PSCO.

[/vc_column_text][/vc_column][/vc_row][vc_row full_width=”stretch_row” css=”.vc_custom_1544614980050{padding-top: 80px !important;padding-bottom: 80px !important;background-color: #e3e3e3 !important;}”][vc_column][ult_buttons btn_title=”PSCO ONCO 2019 AGENDA” btn_link=”url:http%3A%2F%2Fpsco.com.pk%2Fwp-content%2Fuploads%2F2019%2F03%2F23rd-PSCO-ONCO-2019-Peshawar-Agenda-1.pdf||target:%20_blank|” btn_align=”ubtn-center” btn_size=”ubtn-custom” btn_padding_left=”50″ btn_padding_top=”10″ btn_title_color=”#ffffff” btn_bg_color=”#f80000″ icon_size=”32″ btn_icon_pos=”ubtn-sep-icon-at-left” btn_font_family=”font_family:Open Sans|font_call:Open+Sans|variant:600″ btn_font_style=”font-weight:600;” btn_font_size=”desktop:30px;” btn_line_height=”desktop:36px;”][/vc_column][/vc_row][vc_section full_width=”stretch_row_content” css=”.vc_custom_1513044833729{background-color: #2d73b4 !important;}”][vc_row full_width=”stretch_row_content”][vc_column][ultimate_heading main_heading=”Oncology Updates” main_heading_color=”#ffffff” sub_heading_color=”#ffffff” main_heading_font_family=”font_family:Poppins|font_call:Poppins” main_heading_style=”font-style:italic;font-weight:500;” main_heading_font_size=”desktop:36px;” sub_heading_font_family=”font_family:Alegreya|font_call:Alegreya|variant:500italic” sub_heading_style=”font-style:italic;font-weight:500;” sub_heading_font_size=”desktop:36px;” sub_heading_line_height=”desktop:42px;” main_heading_line_height=”desktop:42px;” el_class=”textshadow”][/ultimate_heading][/vc_column][/vc_row][vc_row full_width=”stretch_row_content_no_spaces” css=”.vc_custom_1515339953220{margin-right: 0px !important;margin-left: 0px !important;padding-right: 0px !important;padding-left: 0px !important;}” el_class=”whitelinks”][vc_column css=”.vc_custom_1515339043311{margin-right: 0px !important;margin-left: 0px !important;padding-right: 0px !important;padding-left: 0px !important;}”][ultimate_carousel slide_to_scroll=”single” slides_on_desk=”1″ slides_on_tabs=”1″ slides_on_mob=”1″ autoplay_speed=”6000″ arrows=”off” dots_color=”#ffffff” css_ad_caraousel=”.vc_custom_1515340273496{margin-right: 0px !important;margin-left: 0px !important;padding-right: 0px !important;padding-left: 0px !important;}”][vc_row_inner css=”.vc_custom_1515338991539{margin-right: 0px !important;margin-left: 0px !important;padding-right: 0px !important;padding-left: 0px !important;}”][vc_column_inner css=”.vc_custom_1515338980151{margin-right: 0px !important;margin-left: 0px !important;padding-right: 0px !important;padding-left: 0px !important;}”][vc_column_text el_class=”whitecolor” css=”.vc_custom_1515340143878{margin-bottom: 50px !important;padding-top: 50px !important;padding-right: 50px !important;padding-bottom: 50px !important;padding-left: 50px !important;background-color: #327abd !important;}”]FDA Approves New Treatment for Metastatic Pancreatic Cancer

The US Food and Drug Administration (FDA) has approved the combination of irinotecan liposome injection (Onivyde) plus 5-fluorouracil and leucovorin for the treatment of patients with metastatic pancreatic cancer whose disease has progressed on gemcitabine-based chemotherapy. The drug is a nanotherapeutic that consists of irinotecan molecules encapsulated in a 100 mm liposome sphere.

Read More[/vc_column_text][vc_empty_space height=”35px”][vc_column_text el_class=”whitecolor” css=”.vc_custom_1515340160605{margin-bottom: 50px !important;padding-top: 50px !important;padding-right: 50px !important;padding-bottom: 50px !important;padding-left: 50px !important;background-color: #327abd !important;}”]Ductal Carcinoma in Situ Is Not Cancer

September 25, 2016—Chicago—Lesions called ductal carcinoma in situ (DCIS) possess enormous tumor heterogeneity and varying propensity for progression. They should not all be treated the same, and fail to meet the accepted definition of cancer.

Read More[/vc_column_text][/vc_column_inner][/vc_row_inner][vc_row_inner css=”.vc_custom_1515338991539{margin-right: 0px !important;margin-left: 0px !important;padding-right: 0px !important;padding-left: 0px !important;}”][vc_column_inner css=”.vc_custom_1515338980151{margin-right: 0px !important;margin-left: 0px !important;padding-right: 0px !important;padding-left: 0px !important;}”][vc_column_text el_class=”whitecolor” css=”.vc_custom_1515340174501{margin-bottom: 50px !important;padding-top: 50px !important;padding-right: 50px !important;padding-bottom: 50px !important;padding-left: 50px !important;background-color: #327abd !important;}”]FDA Approves Nivolumab, First Immunotherapy for Lung Cancer

Nivolumab (Opdivo, Bristol-Myers Squibb Company) is the first immunotherapy to be available for use in the treatment of lung cancer. The drug has just been approved by the US Food and Drug Administration (FDA) for use in patients with advanced/metastatic squamous non–small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.

Read More[/vc_column_text][vc_empty_space height=”35px”][vc_column_text el_class=”whitecolor” css=”.vc_custom_1515340185564{margin-bottom: 50px !important;padding-top: 50px !important;padding-right: 50px !important;padding-bottom: 50px !important;padding-left: 50px !important;background-color: #327abd !important;}”]FDA Approves Opdivo to Treat Advanced Form of Kidney Cancer

The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy.

Read More[/vc_column_text][/vc_column_inner][/vc_row_inner][vc_row_inner css=”.vc_custom_1515338991539{margin-right: 0px !important;margin-left: 0px !important;padding-right: 0px !important;padding-left: 0px !important;}”][vc_column_inner css=”.vc_custom_1515338980151{margin-right: 0px !important;margin-left: 0px !important;padding-right: 0px !important;padding-left: 0px !important;}”][vc_column_text el_class=”whitecolor” css=”.vc_custom_1515340204383{margin-bottom: 50px !important;padding-top: 50px !important;padding-right: 50px !important;padding-bottom: 50px !important;padding-left: 50px !important;background-color: #327abd !important;}”]FDA Approves Ramucirumab (Cyramza) for Gastric Cancer

The US Food and Drug Administration has approved the angiogenesis inhibitor ramucirumab (Cyramza) for the treatment of advanced gastric cancer and adenocarcinoma of the gastroesophageal junction. The new drug is intended as a second-line agent for patients with unresectable or metastatic disease following treatment with a fluoropyrimidine- or platinum-containing therapy.
The trial that led to the approval, the REGARD trial, was an international phase III trial that included 355 patients with unresectable or metastatic gastric or gastroesophageal junction cancer. Patients were randomized 2:1 to either treatment with ramucirumab (n = 238) or placebo (n = 117).

Read More[/vc_column_text][/vc_column_inner][/vc_row_inner][/ultimate_carousel][/vc_column][/vc_row][vc_row][vc_column css=”.vc_custom_1513045419927{padding-top: 10px !important;}”][/vc_column][/vc_row][/vc_section][vc_section full_width=”stretch_row_content” css=”.vc_custom_1513047632000{background-image: url(http://psco.com.pk/wp-content/uploads/2017/12/rowbg1-1.jpg?id=118) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][vc_row full_width=”stretch_row”][vc_column css=”.vc_custom_1513046147560{padding-top: 50px !important;padding-bottom: 50px !important;}”][ultimate_heading main_heading=”ONCO MEMOIRS” main_heading_color=”#ffffff” sub_heading_color=”#ffffff” main_heading_font_family=”font_family:Poppins|font_call:Poppins|variant:600″ main_heading_style=”font-weight:600;” main_heading_font_size=”desktop:36px;” sub_heading_font_family=”font_family:Alegreya|font_call:Alegreya|variant:500italic” sub_heading_style=”font-style:italic;font-weight:500;” sub_heading_font_size=”desktop:36px;” sub_heading_line_height=”desktop:42px;” main_heading_line_height=”desktop:42px;” el_class=”textshadow”][/ultimate_heading][ultimate_heading main_heading=”Reminisce The Previous ONCOS Through Gallery” main_heading_color=”#ffffff” sub_heading_color=”#ffffff” main_heading_font_family=”font_family:Poppins|font_call:Poppins” main_heading_style=”font-weight:500;” main_heading_font_size=”desktop:26px;” main_heading_line_height=”desktop:30px;” main_heading_margin=”margin-bottom:0px;” sub_heading_font_family=”font_family:Poppins|font_call:Poppins” sub_heading_style=”font-weight:500;” sub_heading_font_size=”desktop:26px;” sub_heading_line_height=”desktop:30px;” sub_heading_margin=”margin-top:0px;margin-bottom:30px;” el_class=”textshadow”][/ultimate_heading][ult_buttons btn_title=”Go To Archive” btn_link=”url:http%3A%2F%2Fpsco.com.pk%2Farchives%2F|||” btn_align=”ubtn-center” btn_size=”ubtn-custom” btn_padding_left=”50″ btn_padding_top=”10″ btn_title_color=”#ffffff” btn_bg_color=”#f80000″ icon_size=”32″ btn_icon_pos=”ubtn-sep-icon-at-left” btn_font_family=”font_family:Open Sans|font_call:Open+Sans|variant:600″ btn_font_style=”font-weight:600;” btn_font_size=”desktop:30px;” btn_line_height=”desktop:36px;”][/vc_column][/vc_row][/vc_section][vc_section full_width=”stretch_row_content” css=”.vc_custom_1513048210006{background-color: #ffffff !important;}”][vc_row][vc_column][ultimate_heading main_heading=”ONCO LINKS” main_heading_color=”#3c3b3b” main_heading_font_family=”font_family:Open Sans|font_call:Open+Sans” main_heading_font_size=”desktop:24px;” main_heading_line_height=”desktop:28px;” main_heading_margin=”margin-top:50px;margin-bottom:50px;”][/ultimate_heading][vc_row_inner][vc_column_inner width=”1/6″][vc_single_image image=”643″ img_size=”full” alignment=”center” onclick=”custom_link” img_link_target=”_blank” link=”https://www.medscape.com/oncology”][/vc_column_inner][vc_column_inner width=”1/6″][vc_single_image image=”641″ img_size=”full” alignment=”center” onclick=”custom_link” link=”http://www.asco.org/”][/vc_column_inner][vc_column_inner width=”1/6″][vc_single_image image=”630″ img_size=”full” alignment=”center” onclick=”custom_link” link=”https://www.astro.org/home/”][/vc_column_inner][vc_column_inner width=”1/6″][vc_single_image image=”631″ img_size=”full” alignment=”center” onclick=”custom_link” link=”http://www.esmo.org/”][/vc_column_inner][vc_column_inner width=”1/6″][vc_single_image image=”632″ img_size=”full” alignment=”center” onclick=”custom_link” link=”https://www.nccn.org/”][/vc_column_inner][vc_column_inner width=”1/6″][vc_single_image image=”636″ img_size=”full” alignment=”center” onclick=”custom_link” link=”http://www.redjournal.org/”][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][/vc_section][vc_section full_width=”stretch_row” css=”.vc_custom_1513077509634{background-image: url(http://psco.com.pk/wp-content/uploads/2017/12/rowbg2.jpg?id=125) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][vc_row][vc_column][ultimate_heading main_heading=”OUR COUNCIL” main_heading_color=”#ffffff” sub_heading_color=”#ffffff” main_heading_font_family=”font_family:Poppins|font_call:Poppins|variant:600″ main_heading_style=”font-weight:600;” main_heading_font_size=”desktop:36px;” main_heading_line_height=”desktop:40px;” sub_heading_font_family=”font_family:Poppins|font_call:Poppins|variant:500″ sub_heading_style=”font-weight:500;” sub_heading_font_size=”desktop:24px;” sub_heading_line_height=”desktop:28px;” el_class=”textshadow”][/ultimate_heading][/vc_column][/vc_row][vc_row][vc_column][ultimate_carousel slides_on_desk=”4″ slides_on_mob=”1″ arrow_color=”#ffffff” dots=”off” pauseohover=””][vc_row_inner][vc_column_inner][vc_single_image image=”565″ img_size=”full” css=”.vc_custom_1514897209995{margin-bottom: 0px !important;}” el_class=”nomarginimg”][ultimate_heading main_heading=”Dr. Muhammad Ali Memon” main_heading_color=”#ffffff” sub_heading_color=”#ffffff” alignment=”left” main_heading_font_family=”font_family:Open Sans|font_call:Open+Sans” main_heading_font_size=”desktop:18px;” main_heading_line_height=”desktop:22px;” main_heading_margin=”margin-bottom:15px;” sub_heading_font_family=”font_family:Open Sans|font_call:Open+Sans|variant:600″ sub_heading_style=”font-weight:600;” sub_heading_font_size=”desktop:20px;” sub_heading_line_height=”desktop:24px;” el_class=”textshadow”]Senior Vice President PSCO[/ultimate_heading][/vc_column_inner][/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”1005″ img_size=”full” css=”.vc_custom_1533116705232{margin-bottom: 0px !important;}” el_class=”nomarginimg”][ultimate_heading main_heading=”Dr. Humera Mehmood” main_heading_color=”#ffffff” sub_heading_color=”#ffffff” alignment=”left” main_heading_font_family=”font_family:Open Sans|font_call:Open+Sans” main_heading_font_size=”desktop:18px;” main_heading_line_height=”desktop:22px;” main_heading_margin=”margin-bottom:15px;” sub_heading_font_family=”font_family:Open Sans|font_call:Open+Sans|variant:600″ sub_heading_style=”font-weight:600;” sub_heading_font_size=”desktop:20px;” sub_heading_line_height=”desktop:24px;” el_class=”textshadow”]Vice President PSCO[/ultimate_heading][/vc_column_inner][/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”567″ img_size=”full” css=”.vc_custom_1514897320083{margin-bottom: 0px !important;}” el_class=”nomarginimg”][ultimate_heading main_heading=”Prof. Ahmed Ijaz Masood” main_heading_color=”#ffffff” sub_heading_color=”#ffffff” alignment=”left” main_heading_font_family=”font_family:Open Sans|font_call:Open+Sans” main_heading_font_size=”desktop:18px;” main_heading_line_height=”desktop:22px;” main_heading_margin=”margin-bottom:15px;” sub_heading_font_family=”font_family:Open Sans|font_call:Open+Sans|variant:600″ sub_heading_style=”font-weight:600;” sub_heading_font_size=”desktop:20px;” sub_heading_line_height=”desktop:24px;” el_class=”textshadow”]General Secretary PSCO[/ultimate_heading][/vc_column_inner][/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”568″ img_size=”full” css=”.vc_custom_1514900344904{margin-bottom: 0px !important;}” el_class=”nomarginimg”][ultimate_heading main_heading=”Dr. Jawad Akhter Gilani” main_heading_color=”#ffffff” sub_heading_color=”#ffffff” alignment=”left” main_heading_font_family=”font_family:Open Sans|font_call:Open+Sans” main_heading_font_size=”desktop:18px;” main_heading_line_height=”desktop:22px;” main_heading_margin=”margin-bottom:15px;” sub_heading_font_family=”font_family:Open Sans|font_call:Open+Sans|variant:600″ sub_heading_style=”font-weight:600;” sub_heading_font_size=”desktop:20px;” sub_heading_line_height=”desktop:24px;” el_class=”textshadow”]Joint Secretary PSCO[/ultimate_heading][/vc_column_inner][/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”569″ img_size=”full” css=”.vc_custom_1514900386867{margin-bottom: 0px !important;}” el_class=”nomarginimg”][ultimate_heading main_heading=”Dr. Azhar Rashid” main_heading_color=”#ffffff” sub_heading_color=”#ffffff” alignment=”left” main_heading_font_family=”font_family:Open Sans|font_call:Open+Sans” main_heading_font_size=”desktop:18px;” main_heading_line_height=”desktop:22px;” main_heading_margin=”margin-bottom:15px;” sub_heading_font_family=”font_family:Open Sans|font_call:Open+Sans|variant:600″ sub_heading_style=”font-weight:600;” sub_heading_font_size=”desktop:20px;” sub_heading_line_height=”desktop:24px;” el_class=”textshadow”]Joint Secretary PSCO[/ultimate_heading][/vc_column_inner][/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”570″ img_size=”full” css=”.vc_custom_1514900424426{margin-bottom: 0px !important;}” el_class=”nomarginimg”][ultimate_heading main_heading=”Dr. Asghar H. Asghar” main_heading_color=”#ffffff” sub_heading_color=”#ffffff” alignment=”left” main_heading_font_family=”font_family:Open Sans|font_call:Open+Sans” main_heading_font_size=”desktop:18px;” main_heading_line_height=”desktop:22px;” main_heading_margin=”margin-bottom:15px;” sub_heading_font_family=”font_family:Open Sans|font_call:Open+Sans|variant:600″ sub_heading_style=”font-weight:600;” sub_heading_font_size=”desktop:20px;” sub_heading_line_height=”desktop:24px;” el_class=”textshadow”]Finance Secretary PSCO[/ultimate_heading][/vc_column_inner][/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”571″ img_size=”full” css=”.vc_custom_1514900503046{margin-bottom: 0px !important;}” el_class=”nomarginimg”][ultimate_heading main_heading=”Dr. Rab Nawaz Maken” main_heading_color=”#ffffff” sub_heading_color=”#ffffff” alignment=”left” main_heading_font_family=”font_family:Open Sans|font_call:Open+Sans” main_heading_font_size=”desktop:18px;” main_heading_line_height=”desktop:22px;” main_heading_margin=”margin-bottom:15px;” sub_heading_font_family=”font_family:Open Sans|font_call:Open+Sans|variant:600″ sub_heading_style=”font-weight:600;” sub_heading_font_size=”desktop:20px;” sub_heading_line_height=”desktop:24px;” el_class=”textshadow”]CME Coordinator PSCO[/ultimate_heading][/vc_column_inner][/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”623″ img_size=”full” css=”.vc_custom_1515332340981{margin-bottom: 0px !important;}” el_class=”nomarginimg”][ultimate_heading main_heading=”Dr. Ghulam Haider” main_heading_color=”#ffffff” sub_heading_color=”#ffffff” alignment=”left” main_heading_font_family=”font_family:Open Sans|font_call:Open+Sans” main_heading_font_size=”desktop:18px;” main_heading_line_height=”desktop:22px;” main_heading_margin=”margin-bottom:15px;” sub_heading_font_family=”font_family:Open Sans|font_call:Open+Sans|variant:600″ sub_heading_style=”font-weight:600;” sub_heading_font_size=”desktop:20px;” sub_heading_line_height=”desktop:24px;” el_class=”textshadow”]Medical Oncologist (JPMC)[/ultimate_heading][/vc_column_inner][/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”626″ img_size=”full” css=”.vc_custom_1515414680711{margin-bottom: 0px !important;}” el_class=”nomarginimg”][ultimate_heading main_heading=”Dr. Yasmin Rashid” main_heading_color=”#ffffff” sub_heading_color=”#ffffff” alignment=”left” main_heading_font_family=”font_family:Open Sans|font_call:Open+Sans” main_heading_font_size=”desktop:18px;” main_heading_line_height=”desktop:22px;” main_heading_margin=”margin-bottom:15px;” sub_heading_font_family=”font_family:Open Sans|font_call:Open+Sans|variant:600″ sub_heading_style=”font-weight:600;” sub_heading_font_size=”desktop:20px;” sub_heading_line_height=”desktop:24px;” el_class=”textshadow”]Medical Oncologist (AKUH)[/ultimate_heading][/vc_column_inner][/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”958″ img_size=”full” css=”.vc_custom_1515414688211{margin-bottom: 0px !important;}” el_class=”nomarginimg”][ultimate_heading main_heading=”Dr. Nadeem Paracha” main_heading_color=”#ffffff” sub_heading_color=”#ffffff” alignment=”left” main_heading_font_family=”font_family:Open Sans|font_call:Open+Sans” main_heading_font_size=”desktop:18px;” main_heading_line_height=”desktop:22px;” main_heading_margin=”margin-bottom:15px;” sub_heading_font_family=”font_family:Open Sans|font_call:Open+Sans|variant:600″ sub_heading_style=”font-weight:600;” sub_heading_font_size=”desktop:20px;” sub_heading_line_height=”desktop:24px;” el_class=”textshadow”]Medical Oncologist (CMH Multan)[/ultimate_heading][/vc_column_inner][/vc_row_inner][/ultimate_carousel][/vc_column][/vc_row][/vc_section]